{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:35:12Z","timestamp":1767792912578,"version":"3.49.0"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are limited data exploring the outcome following SARS-CoV-2 infection in fibrotic interstitial lung disease (fILD). Our goal was to determine the association of vaccination for SARS-CoV-2 with both SARS-CoV-2 infection and subsequent 90-day mortality in fILD. Our second objective was to determine the association of immunosuppressive use with both SARS-CoV-2 infection and subsequent 90-day mortality in fILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with fILD enrolled in the Canadian Registry for Pulmonary Fibrosis with comprehensive access to data on SARS-CoV-2 vaccination and PCR-confirmed infection were included. Associations of vaccination status and current immunosuppressant use with SARS-CoV-2 infection and subsequent 90-day mortality were tested using Fisher\u2019s exact test and subsequently multivariable logistic regression adjusting for age, sex, pre-identified comorbidities, forced vital capacity and diffusing capacity of the lung for carbon monoxide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1452 total patients with fILD, 138 tested positive for SARS-CoV-2. On adjusted analysis, vaccination for SARS-CoV-2 was associated with a 60% reduction in the odds of infection (OR 0.40, 95%\u2009CI 0.24 to 0.67\u2009p&lt;0.001) and a 97% reduction in the odds of 90-day mortality following infection (OR 0.03, 95%\u2009CI 0.0007 to 0.26, p=0.01). SARS-CoV-2 was diagnosed in 13% of patients on an immunosuppressant and 9% of those not (OR 1.4, 95%\u2009CI 1.0 to 2.1, p=0.04). Immunosuppressant use was not associated with 90-day mortality after SARS-CoV-2 infection on adjusted analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with fILD, vaccination against SARS-CoV-2 was associated with decreased frequency of SARS-CoV-2 infection and subsequent 90-day mortality, while current use of immunosuppressive medication was associated with risk of infection but only a trend for subsequent 90-day mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-003008","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T21:15:26Z","timestamp":1750799726000},"page":"e003008","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Association of vaccination status and immunosuppression with mortality of SARS-CoV-2 infection in patients with fibrotic interstitial lung disease"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4210-1368","authenticated-orcid":false,"given":"Kathryn","family":"Donohoe","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri A","family":"Johannson","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Alberta, Canada"},{"name":"Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Manganas","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine, Centre de Recherche du Centre Hospitalier de l\u2019Universite de Montreal, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-3227","authenticated-orcid":false,"given":"Veronica","family":"Marcoux","sequence":"additional","affiliation":[{"name":"Medicine, University of Saskatchewan College of Medicine, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J","family":"Ryerson","sequence":"additional","affiliation":[{"name":"Medicine, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2026010701505941000_12.1.e003008.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2026010701505941000_12.1.e003008.2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1164\/rccm.202007-2794OC","article-title":"Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study","volume":"202","author":"Drake","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701505941000_12.1.e003008.3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1164\/rccm.202007-2638LE","article-title":"Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease","volume":"203","author":"Gallay","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701505941000_12.1.e003008.4","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29098","article-title":"Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic","volume":"95","author":"Shao","year":"2023","journal-title":"J Med Virol"},{"key":"2026010701505941000_12.1.e003008.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04474-2020"},{"key":"2026010701505941000_12.1.e003008.6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1164\/rccm.202006-2441LE","article-title":"Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study","volume":"202","author":"Esposito","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701505941000_12.1.e003008.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04125-2020"},{"key":"2026010701505941000_12.1.e003008.8","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.3390\/jcm11092437","article-title":"Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease","volume":"11","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"J Clin Med"},{"key":"2026010701505941000_12.1.e003008.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.19766","article-title":"Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis","volume":"6","author":"Januel","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026010701505941000_12.1.e003008.10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e19542","article-title":"COVID-19 infection in patients on anti-CD20 monoclonal antibodies: Changes in clinical outcomes and management over time","volume":"41","author":"Ali","year":"2023","journal-title":"JCO"},{"key":"2026010701505941000_12.1.e003008.11","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/art.41800","article-title":"Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals","volume":"73","author":"England","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026010701505941000_12.1.e003008.12","first-page":"e1870","article-title":"Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2026010701505941000_12.1.e003008.13","first-page":"3562923","article-title":"The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry","volume":"2016","author":"Ryerson","year":"2016","journal-title":"Can Respir J"},{"key":"2026010701505941000_12.1.e003008.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"2026010701505941000_12.1.e003008.15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/acsptsci.2c00181","article-title":"Association of COVID-19 with Comorbidities: An Update","volume":"6","author":"Chatterjee","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026010701505941000_12.1.e003008.16","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03647-20","article-title":"Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis","volume":"12","author":"Ng","year":"2021","journal-title":"MBio"},{"key":"2026010701505941000_12.1.e003008.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2026010701505941000_12.1.e003008.18","doi-asserted-by":"publisher","DOI":"10.1093\/9je\/dyaa134"},{"key":"2026010701505941000_12.1.e003008.19","doi-asserted-by":"publisher","DOI":"10.15585\/MMWR.MM7034E2"},{"key":"2026010701505941000_12.1.e003008.20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S2213-2600(21)00095-3","article-title":"Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study","volume":"9","author":"Aveyard","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026010701505941000_12.1.e003008.21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7038e1"},{"key":"2026010701505941000_12.1.e003008.22","doi-asserted-by":"crossref","first-page":"17534666221117002","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"van den Bosch","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2026010701505941000_12.1.e003008.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70175-6"},{"key":"2026010701505941000_12.1.e003008.24","unstructured":"Coronavirus disease 2019 (covid-19) treatment guidelines. Bethesda (MD): National Institutes of Health (US); 2021. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570371\/"},{"key":"2026010701505941000_12.1.e003008.25","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2026010701505941000_12.1.e003008.26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 \u2014 COVID-NET, 10 States, March 2020\u2013February 2022","volume":"71","author":"Singson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026010701505941000_12.1.e003008.27","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026010701505941000_12.1.e003008.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219498"},{"key":"2026010701505941000_12.1.e003008.29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad181"},{"key":"2026010701505941000_12.1.e003008.30","doi-asserted-by":"crossref","unstructured":"Musche V , Kohler H , B\u00e4uerle A , et al . n.d. COVID-19-Related Fear, Risk Perception, and Safety Behavior in Individuals with Diabetes. Healthcare (Basel) 9:480. doi:10.3390\/healthcare9040480","DOI":"10.3390\/healthcare9040480"},{"key":"2026010701505941000_12.1.e003008.31","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3389\/fpsyg.2020.01984","article-title":"COVID-19-Related Fear and Health-Related Safety Behavior in Oncological Patients","volume":"11","author":"Musche","year":"2020","journal-title":"Front Psychol"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-003008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:52:14Z","timestamp":1767779534000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-003008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjresp-2024-003008"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-003008","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}